Agenus (AGEN) Set to Announce Quarterly Earnings on Thursday

Key Points

• Agenus is expected to report Q3 2026 results before the market opens on November 5, with analysts forecasting $0.02 in EPS and $28.20 million in revenue.
• The company’s previous quarter fell short of earnings expectations, reporting a $0.01-per-share loss versus the projected $0.05 loss, while revenue of $34.52 million exceeded estimates.
• Agenus shares have risen 7.2%, and analysts maintain a “Moderate Buy” consensus with an average price target of $24.50, despite mixed ratings and continued projected losses.

Agenus (NASDAQ:AGEN - Get Free Report) is expected to announce its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Agenus to announce earnings of $0.02 per share and revenue of $28.20 million for the quarter. Interested persons may visit the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 7:30 AM ET.

Agenus (NASDAQ:AGEN - Get Free Report) last issued its earnings results on Friday, August 7th. The biotechnology company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.06). The firm had revenue of $34.52 million during the quarter, compared to analysts' expectations of $34.00 million. Agenus had a negative return on equity of 47.68% and a net margin of 69.33%. On average, analysts expect Agenus to post ($0.30) EPS for the current fiscal year and ($0.47) EPS for the next fiscal year.

Agenus Stock Up 7.2%

Shares of AGEN opened at $7.13 on Thursday. The stock has a market capitalization of $322.01 million, a P/E ratio of 2.76 and a beta of 1.31. The firm has a fifty day simple moving average of $7.63 and a two-hundred day simple moving average of $4.91. Agenus has a twelve month low of $2.71 and a twelve month high of $10.31.

Analyst Ratings Changes

A number of research firms have commented on AGEN. Rodman & Renshaw assumed coverage on Agenus in a research report on Monday, September 28th. They set a "buy" rating and a $19.00 price target for the company. Chardan Capital reaffirmed a "buy" rating on shares of Agenus in a research report on Thursday, October 22nd. B. Riley Financial reiterated a "buy" rating and set a $14.00 target price (up from $8.00) on shares of Agenus in a report on Thursday, July 30th. HC Wainwright reissued a "buy" rating and issued a $25.00 target price (down from $30.00) on shares of Agenus in a research report on Tuesday, August 11th. Finally, Weiss Ratings raised shares of Agenus from a "sell (d)" rating to a "sell (d+)" rating in a research report on Thursday, October 8th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $24.50.

Agenus Company Profile

Agenus Inc is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company's research programs are designed to activate and strengthen the immune system's ability to recognize and attack tumors, with a focus on therapies that may be used across multiple cancer types.

Agenus develops a range of therapeutic approaches, including immune checkpoint inhibitors, cancer vaccines, bispecific antibodies and other antibody-based treatments. Its pipeline has included investigational therapies targeting immune-regulating pathways, as well as combination regimens intended to improve treatment responses and address resistance to existing cancer therapies.

The company was founded in 1994 as Antigenics and adopted the Agenus name in 2011.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.